{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:14:00Z","timestamp":1786979640289,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["7462RH"],"award-info":[{"award-number":["7462RH"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00125-018-4806-9","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T08:54:42Z","timestamp":1547110482000},"page":"621-632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study"],"prefix":"10.1007","volume":"62","author":[{"name":"on behalf of the Scottish Diabetes Research Network Epidemiology Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"McGurnaghan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Brierley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Caparrotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"McKeigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke A. K.","family":"Blackbourn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham P.","family":"Leese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory J.","family":"McCrimmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"McKnight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan R.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Colhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"key":"4806_CR1","unstructured":"AstraZeneca AB (2017) Forxiga (dapagliflozin). Summary of product characteristics. Available from \n                    https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/forxiga\n                    \n                  , accessed 8 Sep 2017"},{"key":"4806_CR2","unstructured":"US Food & Drug Administration (2014) Center For Drug Evaluation And Research Summary review [Farxiga]. Available from \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/202293Orig1s000SumR.pdf\n                    \n                  . Accessed 24 Sep 2018"},{"issue":"4","key":"4806_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2337\/dc08-1863","volume":"32","author":"JF List","year":"2009","unstructured":"List JF, Woo V, Morales E et al (2009) Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32(4):650\u2013657. \n                    https:\/\/doi.org\/10.2337\/dc08-1863","journal-title":"Diabetes Care"},{"issue":"6","key":"4806_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","volume":"156","author":"JP Wilding","year":"2012","unstructured":"Wilding JP, Woo V, Soler NG et al (2012) Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin - a randomized trial. Ann Intern Med 156(6):405\u2013415. \n                    https:\/\/doi.org\/10.7326\/0003-4819-156-6-201203200-00003","journal-title":"Ann Intern Med"},{"issue":"10","key":"4806_CR5","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2337\/dc10-0612","volume":"33","author":"E Ferrannini","year":"2010","unstructured":"Ferrannini E, Ramos SJ, Salsali A et al (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33(10):2217\u20132224. \n                    https:\/\/doi.org\/10.2337\/dc10-0612","journal-title":"Diabetes Care"},{"issue":"9733","key":"4806_CR6","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A et al (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375(9733):2223\u20132233. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(10)60407-2","journal-title":"Lancet"},{"issue":"7","key":"4806_CR7","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2337\/dc11-1693","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"Rosenstock J, Vico M, Wei L et al (2012) Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35(7):1473\u20131478. \n                    https:\/\/doi.org\/10.2337\/dc11-1693","journal-title":"Diabetes Care"},{"issue":"2","key":"4806_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/dom.12189","volume":"16","author":"J Bolinder","year":"2014","unstructured":"Bolinder J, Ljunggren \u00d6, Johansson L et al (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16(2):159\u2013169. \n                    https:\/\/doi.org\/10.1111\/dom.12189","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"4806_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/dom.12327","volume":"16","author":"MA Nauck","year":"2014","unstructured":"Nauck MA, Del Prato S, Dur\u00e1n-Garc\u00eda S et al (2014) Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab 16(11):1111\u20131120. \n                    https:\/\/doi.org\/10.1111\/dom.12327","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"4806_CR10","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.2337\/dc09-0517","volume":"32","author":"JPH Wilding","year":"2009","unstructured":"Wilding JPH, Norwood P, T\u2019joen C et al (2009) A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32(9):1656\u20131662. \n                    https:\/\/doi.org\/10.2337\/dc09-0517","journal-title":"Diabetes Care"},{"issue":"3","key":"4806_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/dmrr.2479","volume":"30","author":"M Zhang","year":"2014","unstructured":"Zhang M, Zhang L, Wu B et al (2014) Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 30(3):204\u2013221. \n                    https:\/\/doi.org\/10.1002\/dmrr.2479","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"4806_CR12","doi-asserted-by":"publisher","first-page":"e004619","DOI":"10.1136\/bmjopen-2013-004619","volume":"4","author":"Y-N Sun","year":"2014","unstructured":"Sun Y-N, Zhou Y, Chen X et al (2014) The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open 4(4):e004619. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2013-004619","journal-title":"BMJ Open"},{"issue":"3","key":"4806_CR13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren \u00d6, Kullberg J et al (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97(3):1020\u20131031. \n                    https:\/\/doi.org\/10.1210\/jc.2011-2260","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"4806_CR14","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. NEJM 373(22):2117\u20132128. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"NEJM"},{"issue":"7","key":"4806_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. NEJM 377(7):644\u2013657. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"NEJM"},{"issue":"5","key":"4806_CR16","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/dom.13217","volume":"20","author":"I Raz","year":"2018","unstructured":"Raz I, Mosenzon O, Bonaca MP et al (2018) DECLARE-TIMI 58: participants\u2019 baseline characteristics. Diabetes Obes Metab 20(5):1102\u20131110. \n                    https:\/\/doi.org\/10.1111\/dom.13217","journal-title":"Diabetes Obes Metab"},{"key":"4806_CR17","unstructured":"Kemp A (2018) Farxiga achieved a positive result in the Phase III DECLARE-TIMI 58 trial, a large cardiovascular outcomes trial in 17,000 patients with type-2 diabetes. Available from \n                    https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2018\/farxiga-achieved-a-positive-result-in-the-phase-iii-declare-timi-58-trial-a-large-cardiovascular-outcomes-trial-in-17000-patients-with-type-2-diabetes-24092018.html\n                    \n                  , accessed 24 Sep 2018"},{"issue":"9","key":"4806_CR18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","volume":"5","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Avogaro A (2017) SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol 5(9):680\u2013681. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(17)30257-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"4806_CR19","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Ferrannini E (2015) Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38(9):1638\u20131642. \n                    https:\/\/doi.org\/10.2337\/dc15-1380","journal-title":"Diabetes Care"},{"key":"4806_CR20","unstructured":"US Food & Drug Administration (2015) FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available from \n                    https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463.htm\n                    \n                  . Accessed 28 Oct 2017"},{"issue":"9453","key":"4806_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM (2005) External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply?\u201d. Lancet 365(9453):82\u201393. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(04)17670-8","journal-title":"Lancet"},{"issue":"23","key":"4806_CR22","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ et al (2016) Real-world evidence \u2014 what is it and what can it tell us? N Engl J Med 375(23):2293\u20132297. \n                    https:\/\/doi.org\/10.1056\/NEJMsb1609216","journal-title":"N Engl J Med"},{"issue":"12","key":"4806_CR23","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1111\/j.1464-5491.2011.03432.x","volume":"28","author":"H Anwar","year":"2011","unstructured":"Anwar H, Fischbacher C, Leese G et al (2011) Assessment of the under-reporting of diabetes in hospital admission data: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabet Med 28(12):1514\u20131519. \n                    https:\/\/doi.org\/10.1111\/j.1464-5491.2011.03432.x","journal-title":"Diabet Med"},{"issue":"10","key":"4806_CR24","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1007\/s00125-016-4054-9","volume":"59","author":"SH Read","year":"2016","unstructured":"Read SH, Kerssens JJ, McAllister DA et al (2016) Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. Diabetologia 59(10):2106\u20132113. \n                    https:\/\/doi.org\/10.1007\/s00125-016-4054-9","journal-title":"Diabetologia"},{"issue":"4","key":"4806_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2307\/2529876","volume":"38","author":"NM Laird","year":"1982","unstructured":"Laird NM, Ware JH (1982) Random-effects models for longitudinal data. Biometrics 38(4):963\u2013974. \n                    https:\/\/doi.org\/10.2307\/2529876","journal-title":"Biometrics"},{"issue":"12","key":"4806_CR26","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/pds.4327","volume":"26","author":"B Farran","year":"2017","unstructured":"Farran B, McGurnaghan S, Looker HC et al (2017) Modelling cumulative exposure for inference about drug effects in observational studies. Pharmacoepidemiol Drug Saf 26(12):1527\u20131533. \n                    https:\/\/doi.org\/10.1002\/pds.4327","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"4806_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2337\/dc14-0666","volume":"38","author":"S Matthaei","year":"2015","unstructured":"Matthaei S, Bowering K, Rohwedder K et al (2015) Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 38(3):365\u2013372. \n                    https:\/\/doi.org\/10.2337\/dc14-0666","journal-title":"Diabetes Care"},{"issue":"11","key":"4806_CR28","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.2337\/dc15-0779","volume":"38","author":"C Mathieu","year":"2015","unstructured":"Mathieu C, Ranetti AE, Li D et al (2015) Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care 38(11):2009\u20132017. \n                    https:\/\/doi.org\/10.2337\/dc15-0779","journal-title":"Diabetes Care"},{"issue":"3","key":"4806_CR29","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2337\/dc13-0467","volume":"37","author":"SA Jabbour","year":"2014","unstructured":"Jabbour SA, Hardy E, Sugg J et al (2014) Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 37(3):740\u2013750. \n                    https:\/\/doi.org\/10.2337\/dc13-0467","journal-title":"Diabetes Care"},{"issue":"3","key":"4806_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","volume":"4","author":"MA Weber","year":"2016","unstructured":"Weber MA, Mansfield TA, Cain VA et al (2016) Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 4(3):211\u2013220. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(15)00417-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"4806_CR31","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"JP Fr\u00edas","year":"2016","unstructured":"Fr\u00edas JP, Guja C, Hardy E et al (2016) Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4(12):1004\u20131016. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(16)30267-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4806_CR32","unstructured":"US Food & Drug Administration (2013) Center for drug evaluation and research medical review [Farxiga]. Available from \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/202293Orig1s000MedR.pdf\n                    \n                  . Accessed 24 Sep 2018"},{"key":"4806_CR33","unstructured":"National Institute for Health and Care Excellence (2013) Final appraisal determination: dapagliflozin in combination therapy for treating type 2 diabetes. Available from \n                    https:\/\/www.nice.org.uk\/guidance\/ta288\/documents\/diabetes-type-2-dapagliflozin-final-appraisal-determination-document2\n                    \n                  . Accessed 24 Sep 2018"},{"issue":"5","key":"4806_CR34","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.pcd.2017.04.004","volume":"11","author":"J Wilding","year":"2017","unstructured":"Wilding J, Bailey C, Rigney U et al (2017) Dapagliflozin therapy for type 2 diabetes in primary care: changes in HbA1c, weight and blood pressure over 2 years follow-up. Prim Care Diabetes 11(5):437\u2013444. \n                    https:\/\/doi.org\/10.1016\/j.pcd.2017.04.004","journal-title":"Prim Care Diabetes"},{"issue":"5","key":"4806_CR35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","volume":"27","author":"KM Johnsson","year":"2013","unstructured":"Johnsson KM, Ptaszynska A, Schmitz B et al (2013) Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complicat 27(5):473\u2013478. \n                    https:\/\/doi.org\/10.1016\/j.jdiacomp.2013.05.004","journal-title":"J Diabetes Complicat"},{"issue":"8","key":"4806_CR36","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/dom.12917","volume":"19","author":"H Tang","year":"2017","unstructured":"Tang H, Li D, Zhang J et al (2017) Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 19(8):1106\u20131115. \n                    https:\/\/doi.org\/10.1111\/dom.12917","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-018-4806-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-018-4806-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-018-4806-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T19:02:57Z","timestamp":1578596577000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-018-4806-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["4806"],"URL":"https:\/\/doi.org\/10.1007\/s00125-018-4806-9","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,10]]},"assertion":[{"value":"21 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LBr, SJM, PMM and HMC declare a grant from AstraZeneca for the work under consideration for publication. The following authors have disclosed declarations of interest outside the submitted work: NS received grant and personal fees from Boehringer Ingelheim, personal fees from Janssen, Eli Lilly and Novo Nordisk and a grant from Astra Zeneca; JRP received grant and personal fees from Sanofi Aventis, Quintiles and Janssen, personal fees from ACI clinical, Pfizer, Lilly and Novo Nordisk and non-financial support from Itamar Medical and Merck (Germany); RJM received personal fees for advisory boards from Novo Nordisk, Sanofi Aventis and Lilly and HMC received grants (as part of EU Innovative Medicines programme collaborations) from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company, Pfizer, Roche Pharmaceuticals and Sanofi Aventis and grants from Novo Nordisk. HMC is a shareholder in Bayer and Roche Pharmaceuticals. HMC is on trial steering committees or safety monitoring committees with Eli Lilly, Sanofi and Regeneron, Novartis Pharmaceuticals and Novo Nordisk and receives remuneration via her institution for this. She has received speaker fees and travel expenses for presenting trials she has helped design or other research she has led from Pfizer, Eli Lilly, Sanofi and Regeneron. JAM received grants from Novo Nordisk, Lilly, Merck, Boheringer and GSK and non-financial support from Novo Nordisk. ERP received personal honorarium fees from Lilly, MSD, Novo Nordisk and Astra Zeneca. TMC received a grant from Diabetes UK and the British Heart Foundation. All other members of the writing committee declare that there is no duality of interest associated with their contribution to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}}]}}